The 1st Latin America Symposium on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy - Latin Americ)
|Event Date/Time: Mar 11, 2010||End Date/Time: Mar 14, 2010|
|Early Registration Date: Nov 15, 2009|
|Abstract Submission Date: Nov 01, 2009|
TREATMENT OF NEWLY DIAGNOSED TYPE 2 DM PATIENTS (T2DM): WHAT IS THE FIRST LINE OF THERAPY? FOCUS ON SA
Insulinsensitizers: TZDs â€“ metformin
Insulinsecretagogues â€“ incretins â€“ acarbose â€“ antiobesity drugs
WHAT SHOULD BE THE INITIAL TREATMENT IN PATIENTS WHO FAIL LIFESTYLE MODIFICATIONS?
DIABETES IN SA GENETIC EPIDIOMOLOGY TREATMENT?
Type 1 plus type 2 dm (Lada) (Young/ Adult)
Type 2 in young and adult
TARGETING OBESITY AND METABOLIC SYNDROME: WHAT CAN WE OFFER IN THE FUTURE?
Modulators of fatty acid oxidation? Lipid modifiers?
Appetite regulation by gut hormones?
Appetite regulation by central anorectic drugs. HSD inhibitors?
OBESITY: CAUSE AND DIFFERENT APPROACHES
Obesity in SA â€“ Is it different from Row?
Obesity should be treated at any age?
Which kind of exercise? Aerobic, anaerobic or both? How much and how often?
What is the most effective diet for weight loss?
HYPERTENSION IN DIABETES
Hypertension as a vascular disease
The endothelium as a target for therapy
Assessing vascular and endothelial function in the clinic-implications for diagnosis and management
The vasculature as a central factor in obesity, diabetes and hypertension
UNDERSTANDING THE CAUSE OF HYPERTENSION
Role of SNA
Role of angiotensin-renin system
Role of aldosterone-renin system
CARDIOVASCULAR RISK IN DIABETES FOCUSING ON GENETIC IN SA
Hyperglycemia and cardiovascular disease
Dislipemia and cardiovascular disease
Hypertension and cardiovascular disease
Inflammation and COD
EVIDENCE FROM CLINICAL TRIALS IN DIABETES
Effects of glucose control on CVD
Specific drug effects on CVD
Difference between population on patients from SA
TREATMENT GOALS IN DIABETES
What is the target of HBA1c in insulin T2DM? Focusing on SA
1. Should we focus on A1c or LA1c?
2. Should we aim to normal A1c?
OPTIMIZING DIABETES THERAPHY IN SA
New tools in self glucose monitoring control programmed insulin dose calculation
Cost benefit of self monitoring glucose control in type 2
Continuous Glucose Monitoring (GCM). Who will benefit from it? (Children Everyone ICU setting)
THERAPY IN OBESITY AND DIABETES
Bariatric surgery â€“ what is the optimal procedure and how early should it be offered? Focusing on SA and genetic
Last resort in obese patients
Early in the obese patient with risk factors and failure of conservative therapy
Surgery in type 2 (obese and not obese)
LIPIDS IN DIABETES
The importance of specific lipid depots â€“ are they targets for therapy?
PREVENTION AND TREATMENT OF MICROVASCULAR DISORDER IN MEN AND WOMEN
COMBINATION THERAPY IN HYPERTENSIVE DIABETIC PATIENTS
Modulation of sna
Modulation of angiotensin-renin system
Modulation of aldosterone renin system
DIABETIC FOOT: INTERDISCIPLINARY INTERVENTION, DO WE NEED REGIONAL GUIDELINES?
Infectious disease specialist
INSULIN THERAPY IN TYPE 2 DIABETES
Starting insulin treatment by GPs
Intensification of insulin treatment by GPs
What are the benefits of long acting analogs?
Ultralente and ultrarapid insulin in SA
GESTATIONAL AND PREGESTATIONAL DIABETES
HbA1c or fructosamine: which value is the best?
Dislipidaemia in GDM: fetus impact
Mother and fetal complications
WHAT IS THE OPTIMAL THERAPEUTIC APPROACH TO YOUTH WITH T2DM? IS IT AFFICIANT TO SA?
Insulin, Metformin TZD
Combination therapy and lifestyle modifications (based on preliminary results from TODAY study)
Tracking the metabolic impact of pediatric obesity
Treatment approach of GPâ€™s to patients with Type 2 Diabetes, Focusing on SA
TZDS Vs. DPPH.
GLPI Vs. Sulfoniluria / Insulin.
Combination therapy during early and late diabetes